medigraphic.com
ISSN 2007-6517 (Impreso)

2013, Número 1

<< Anterior Siguiente >>

Rev Latinoam Cir 2013; 3 (1)


Cirugía adrenal en un hospital de tercer nivel

Sandoval SMI, Jiménez GJA, Leonher RKL, Ramírez GLR, Albanés MR, Castelltort CLF, Arreola VSG

Idioma: Español
Referencias bibliográficas: 74
Paginas: 32-37
Archivo PDF: 229.37 Kb.


RESUMEN

Introducción: Los incidentalomas son algunos de los tumores sólidos más comúnmente encontrados en el humano, conllevan a una gran variedad de diagnósticos diferenciales y abarcan un espectro de tumores agresivos. Sin embargo, la mayoría de los incidentalomas son benignos y no requieren intervención.
Material y métodos: Estudio tipo serie de casos. Se evaluaron los expedientes de los pacientes con tumor adrenal diagnosticado por cualquier método radiológico y sometido a adrenalectomía en el Hospital de Especialidades Centro Médico Nacional de Occidente del 2009 al 2012.
Resultados: Se ingresaron 35 pacientes, 22% de ellos eran masculinos (n = 8) y 78% femeninos (n = 27), con una edad promedio de 48 años. El método más utilizado para detectar la presencia del tumor adrenal fue la tomografía axial computada; ésta se realizó en el 94% de los pacientes (n = 33). El diagnóstico prequirúrgico predominante fue de incidentaloma con un porcentaje de 20% (n = 57) seguido de síndrome de Cushing y de Síndrome de Conn, cada uno con 6 casos representando el 17% de los casos cada uno.
Conclusiones: Se observa que la patología se presenta más en el sexo femenino, con 4:1 con respecto al sexo masculino; además se encuentra que el método diagnóstico más comúnmente utilizado es la tomografía axial computada. El adenoma y el mielolipoma fueron los principales diagnósticos histopatológicos encontrados. En nuestro país no existen reportes de dicha entidad patológica de manera general, es por ello la importancia de realizar el análisis de este trabajo de manera adecuada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Prinz RA, Brooks MH, Churchill R et al. Incidental asymptomatic adrenal masses detected by computed tomographic scanning. Is operation required? JAMA. 1982;248(6):701-704.

  2. Mantero F, Arnaldi G. Management approaches to adrenal incidentalomas. A view from Ancona, Italy. Endocrinol Metab Clin North Am. 2000;29(1):107-125.

  3. Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet. 1967;1(7488):468-470.

  4. Dobbie JW. Adrenocortical nodular hyperplasia: the ageing adrenal. J Pathol. 1969;99(1):1-18.

  5. Kloos RT, Gross MD, Francis IR et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484.

  6. Shane Y, Morita MD. Endocrine Surgery. USA: McGrawHill; 2012.

  7. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab. 2003;88(10):4533-4539.

  8. Brunt LM, Moley JF. Adrenal incidentaloma. World J Surg. 2001;25(7): 905-913

  9. Aso Y, Homma Y. A survey on incidental adrenal tumors in Japan. J Urol. 1992;147(6):1478-1481.

  10. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1999;84(2):440-448.

  11. Chan KC, Lit LC, Law EL et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem. 2004;50(4):757-759.

  12. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56(6):354-360.

  13. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland—1970–83. Aust N Z J Surg. 1985;55(5):471-475.

  14. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434.

  15. Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med. 2003;138(5):424-429.

  16. Harding JL, Yeh MW, Robinson BG et al. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust. 2005;182(12):637-640.

  17. Lee JA, Zarnegar R, Shen WT et al. Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the “subclinical” pheochromocytoma. Arch Surg. 2007;142(9):870-873.

  18. Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.

  19. Catargi B, Rigalleau V, Poussin A et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808-5813.

  20. Reimondo G, Pia A, Allasino B et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf). 2007;67(2):225-229.

  21. Ness-Abramof R, Nabriski D, Apovian CM et al. Overnight dexamethasone suppression test: a reliable screen for Cushing’s syndrome in the obese. Obes Res. 2002;10(12):1217-1221.

  22. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609-615.

  23. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193-202.

  24. Glass AR, Zavadil AP 3rd, Halberg F et al. Circadian rhythm of serum cortisol in Cushing’s disease. J Clin Endocrinol Metab. 1984;59(1):161-165.

  25. Refetoff S, Van Cauter E, Fang VS et al. The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing’s syndrome. J Clin Endocrinol Metab. 1985;60(3):527-535.

  26. Orth DN. Cushing’s syndrome. N Engl J Med. 1995;332(12):791-803.

  27. Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002; 222(3): 629-633.

  28. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab. 2005;19(2):277-292.

  29. Gagner M, Lacroix A, Prinz RA, et al. Early experience with laparoscopic approach for adrenalectomy. Surgery. 1993;114(6):1120-1124.

  30. Mansmann G, Lau J, Balk E et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340.

  31. Shen WT, Lim RC, Siperstein AE et al. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg. 1999;134(6):628-631.

  32. Fernandez-Cruz L, Saenz A, Benarroch G et al. Laparoscopic unilateral and bilateral adrenalectomy for Cushing’s syndrome. Transperitoneal and retroperitoneal approaches. Ann Surg. 1996;224(6):727-734.

  33. Cheah WK, Clark OH, Horn JK et al. Laparoscopic adrenalectomy for pheochromocytoma. World J Surg. 2002;26(8):1048-1051.

  34. Duh QY. Laparoscopic adrenalectomy for isolated adrenal metastasis: the right thing to do and the right way to do it. Ann Surg Oncol. 2007;14(12):3288-3289.

  35. Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg. 2002;137(8):948-951.

  36. Henry JF, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg. 2002;26(8):1043-1047.

  37. Read GF, Walker RF, Wilson DW, Griffiths K. Steroid analysis in saliva for the assessment of endocrine function. Ann N Y Acad Sci. 1990;595:260-274.

  38. Barry MK, van Heerden JA, Farley DR et al. Can adrenal incidentalomas be safely observed? World J Surg. 1998;22(6):599-603.

  39. Jockenhovel F, Kuck W, Hauffa B et al. Conservative and surgical management of incidentally discovered adrenal tumors (incidentalomas). J Endocrinol Invest. 1992;15(5):331-337.

  40. Staren ED, Prinz RA. Selection of patients with adrenal incidentalomas for operation. Surg Clin North Am. 1995;75(3):499-509.

  41. Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644.

  42. Vantyghem MC, Ronci N, Provost F et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol. 1999;141(3):279-285.

  43. Conn JW. Diagnosis of normokalemic primary aldosteronism, a new form of curable hypertension. Science. 1967;158(3800):525-526.

  44. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable “essential” hypertension. JAMA. 1965;193:200-206.

  45. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994;23(2):271-283.

  46. Young WF Jr, Hogan MJ, Klee GG et al. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc. 1990;65(1):96-110.

  47. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350(16):1629-1638.

  48. Weingartner K, Gerharz EW, Bittinger A et al. Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma. Case report and review of the literature. Urol Int. 1995;55(4):232-235.

  49. Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology. 1996;198(2):309-312.

  50. Young WF, Stanson AW, Thompson GB et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004;136(6):1227-1235.

  51. Zarnegar R, Bloom AI, Lee J et al. Is adrenal venous sampling necessary in all patients with hyperaldosteronism before adrenalectomy? J Vasc Interv Radiol. 2008;19(1):66-71.

  52. Boland GW, Lee MJ, Gazelle GS et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201-204.

  53. Sturgeon C, Shen WT, Clark OH et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg. 2006;202(3):423-430.

  54. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg. 1997;132(8):914-919.

  55. Szolar DH, Korobkin M, Reittner P et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479-485.

  56. Reinig JW, Doppman JL, Dwyer AJ, Frank J. MRI of indeterminate adrenal masses. AJR Am J Roentgenol. 1986;147(3):493-496.

  57. Caoili EM, Korobkin M, Francis IR et al. Delayed enhanced CT of lipidpoor adrenal adenomas. AJR Am J Roentgenol. 2000;175(5):1411-1415.

  58. Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol. 1989;94(3):275-280.

  59. Korobkin M, Brodeur FJ, Francis IR et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol. 1998;170(3):747-752.

  60. Liddle GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J Clin endocrinol Metab. 1960;20:1539-1560.

  61. Pecori Giraldi F, Pivonello R, Ambrogio AG et al. The dexamethasonesuppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Clin Endocrinol (Oxf). 2007;66(2):251-257.

  62. Wood PJ, Barth JH, Freedman DB et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome-recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997;34(pt 3):222-229.

  63. Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab. 1998;83(2):682-684.

  64. Elamin MB, Murad MH, Mullan R et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553-1562.

  65. Qureshi AC, Bahri A, Breen LA et al. The influence of the route of estrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66(5):632-635.

  66. Reinig JW, Doppman JL, Dwyer AJ et al. Adrenal masses differentiated by MR. Radiology. 1986;158(1):81-84.

  67. Yun M, Kim W, Alnafisi N et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42(12):1795-1799.

  68. Tessonnier L, Sebag F, Palazzo FF et al. Does (18)F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging. 2008;35(11):2018-2025.

  69. Klose M, Lange M, Rasmussen AK et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007;92(4):1326-1333.

  70. Melby JC. Diagnosis and treatment of primary aldosteronism and isolated hypoaldosteronism. Clin Endocrinol Metab. 1985;14(4):977-995.

  71. Gordon RD, Stowasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21(4):315-318.

  72. Barzon L, Scaroni C, Sonino N et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999;84(2):520-526.

  73. Adler JT, Mack E, Chen H. Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol. 2007;14(8):2358-2362.

  74. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol. 2003;15(1):84-90.




2020     |     www.medigraphic.com